Like what you read? Get new posts delivered straight to your inbox!
Contact Us | Follow Us
Experience. Integrity. IMPACT.
What We Do

SYNER-G BIOPHARMA GROUP APPOINTS RON KRAUS AS CEO

RESEARCH TRIANGLE PARK, NC: 13 June 2022

Syner-G BioPharma Group (“Syner-G”), a leading provider of consulting services to pharmaceutical and biotechnology clients, today announced that Ron Kraus has joined the company as Chief Executive Officer (CEO).

Mr. Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions. Prior to joining Syner-G, Ron was Chief Operating Officer at Cytel where he contributed to the exponential growth and enhanced profitability of their Services business. In addition to his leadership experience at Cytel, Mr. Kraus spent two decades at Parexel International in roles of increasing responsibility. During his tenure as the Global Head of Parexel Consulting, a product development consultancy, he led the development and execution of a strategy that drove robust expansion and launched new services, both through organic growth and strategic acquisitions.

Mr. Kraus succeeds Syner-G’s founder, Prabu Nambiar, PhD, MBA, RAC, as CEO. Dr. Nambiar is excited to continue his work at Syner-G with a focus on clients, corporate strategy, and promoting business growth. Dr. Nambiar led Syner-G through a rapid growth phase, including the late 2021 acquisition of Impact Pharmaceutical Services, a highly successful medical writing, regulatory strategy, and regulatory publishing provider.

In announcing Mr. Kraus’s appointment, Dr. Nambiar remarked, “I couldn’t be more excited and pleased to welcome Ron to the Syner-G family. To meet our future strategic needs, we were very rigorous in our search for our next CEO, and I am extremely confident that Ron is the right person, at the right time, to lead Syner-G in its mission to become the preeminent provider of pharmaceutical consulting services worldwide.”

Syner-G is a portfolio company of Riverside Partners, a Boston-based private equity firm focused on helping growth-oriented healthcare and technology companies achieve their next level of success. Craig Stern, a member of Syner-G’s board of directors and a General Partner at Riverside, said, “When looking for Syner-G’s next CEO, we knew there were big shoes to fill. Prabu has led Syner-G from its inception to where it is today – a thriving company of more than 200 employees and close to 200 active clients. The bar was extremely high, and we were focused on finding a leader who has relevant experience, strong domain knowledge, and possesses the right values. We found that person in Ron Kraus.”

“I am humbled to be chosen to lead this extraordinary organization into the future,” Mr. Kraus said. “And I thank Prabu and all of the Syner-G team for the excellent foundation that they’ve established. Syner-G has experienced strong growth, underpinned by high quality services and a reputation for scientific excellence. I see the immense potential of what this team has created, and I am inspired by the collaboration and hard work that’s been invested. I am looking forward to working with this talented team and am committed to being a good steward of that investment.”

About Syner-G BioPharma Group

Headquartered in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, and regulatory submissions and publishing solutions and services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, visit www.synergbiopharma.com.

Media Contact:

Mark A. Cierpial, PhD

SVP, Regulatory Services
Phone: (919) 899-9248
Fax: (919) 354-6090
mcierpial@impactpharma.com
www.impactpharma.com